News

Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the

Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work

The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).

The approval was given after reviewing results from a large clinical program which included over ten multinational clinical trials and more than 13,000 adults with T2D. The Phase

Darinaparsin is a new mitochondrial-targeted agent under development for the treatment of several hematologic and solid cancers. As part of the amended and restated deal, Solasia secured exclusive

CRT 001 (xamoterol fumarate), a selective partial agonist of the beta-1 adrenergic receptor (B1-ADR), is the lead drug candidate in the portfolio acquired by the company. B1-ADR is

The company’s latest innovation provides patient self administration of drugs and biologics formulated as powders for systemic nasal, nose-to-brain, ophthalmic, sublingual and buccal routes of administration. Mystic president

In this trial, the company will evaluate the efficacy and safety of 1% LE-MPP and 0.25% LE-MPP dosed four times daily in patients having measurable intraretinal or subretinal

"The initiation of this human abuse liability study is a key milestone in the development path for CR845," said Robert Medve, M.D., Chief Medical Officer of Cara Therapeutics.